EFMC-ISMC 2014
Conferences > Archives > EFMC-ISMC 2014

Programme Schedule

Sunday September 7, 2014
16:15Opening Ceremony
16:35Portugal: the Right Place to build Partnerships in Health
Dr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)
16:50Partnership between Public and Private Sources: Pharma and IMI Perspective
Dr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)
17:10EFMC Award Ceremony
17:35The Nauta Award for Pharmacochemistry
Pursuing Compound Quality
Dr Paul LEESON
(GLAXOSMITHKLINE, Nuneaton, United Kingdom)
18:20High Resolution Mass Spectrometry in Clinical Proteomics
Prof. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)
19:10Welcome Reception
Monday September 8, 2014
08:30The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Small Molecule Control Of Intracellular Protein Levels
Prof. Craig CREWS
(UNIVERSITY OF YALE, New Haven, United States)
09:15The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery
Thermodynamics Assisted Drug Discovery
Dr György G. FERENCZY (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
Prof. Gyorgy KESERU (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
10:00Exhibition & Coffee
1.1 Inflammation: the Common Link in Multifactorial Disorders?1.2 Computational Approaches To Guide Medicinal Chemistry1.3 Organic Synthesis that Changed Medicinal Chemistry
10:30Session Chair
Dr Angeliki KOUROUNAKIS
(UNIVERSITY OF ATHENS, Athens, Greece)
10:35Inflammation, Obesity and Metabolic Disease
Dr Ajay CHAWLA
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)
11:15CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis
Dr Uwe GRETHER
(F. HOFFMANN-LA-ROCHE, Basel, Switzerland)
11:35The Discovery of APD334, a Selective S1P1 Functional Antagonist
Dr Robert JONES
(ARENA PHARM, SAN DIEGO, United States)
11:55Discovery of Small Molecule Rorγ Modulators for the Treatment of Autoimmune Diseases
Dr Frank NARJES
(ASTRAZENECA, Mölndal, Sweden)
10:30Session Chair
Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)
10:35Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function
Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)
11:15Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter
Dr Chris CHIPOT
(UNIVERSITY OF ILLINOIS, Urbana, United States)
11:35Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?
Dr Clara CHRIST
(BAYER PHARMA, Berlin, Germany)
11:55P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies
Mr Ricardo FERREIRA
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)
10:30Session Chair
Dr Morten JORGENSEN
(H. LUNDBECK A/S, Valby, Denmark)
10:35Recent Advances In Asymmetric Catalysis
Prof. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)
11:15New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids
Prof. Pier Giorgio COZZI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)
11:35Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry
Dr Marc MOSRIN
(BAYER CROPSCIENCE AG, Frankfurt am Main, Germany)
11:55Development of Novel Building Blocks to Accelerate Drug Discovery
Dr Pavel MYKHAILIUK
(ENAMINE, Kyiv, Ukraine)
12:15Exhibition & Lunch
2.4 Combating Antibiotic Resistance2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury
(Eufeps Session)
13:15Session Chair
Prof. Ada YONATH
(WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel)
13:20Aminoglycoside Mechanisms of Action, Resistance and Toxicity – Prospects for Antibiotic Drug Development
Prof. Erik BOËTTGER
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)
14:00Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target
Prof. Stephen DOUTHWAITE
(UNIVERSITY OF SOUTHERN DENMARK, Odensen, Denmark)
14:20The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design
Dr Moran SHALEV BEN AMI
(WEIZMANN INSTITUTE, Rehovot, Israel)
14:40Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents
Dr Martin EMPTING
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)
13:15Session Chair
Prof. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)
13:20Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development
Dr Esther SCHMITT
(NOVARTIS, Basel, Switzerland)
14:00Sponging Off Nature for New Drug Leads
Prof. Raymond ANDERSEN
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)
14:20Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya
Prof. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)
14:40From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein
Dr Fanny ROUSSI
(ICSN - CNRS, Gif sur Yvette, France)
13:15Session Chair
Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)
13:20Mechanism-Based Prediction of Drug-Induced Liver Injury
Dr Christopher GOLDRING
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)
14:00Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites
Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)
14:20Being More Certain About Uncertainty In Computational Toxicology Modeling
Dr Scott BOYER
(KAROLINSKA INSTITUTET, Södertälje, Sweden)
14:40Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?
Dr Alexandra ANTUNES
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)
15:00Exhibition & Coffee
15:30MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application
Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)
3.7 EFMC Session
15:55Session Chair
Dr Phil JONES
(UNIVERSITY OF DUNDEE, Glasgow, United Kingdom)
16:00The Open Phacts Discovery Platform - Semantic Data Integration For Medicinal Chemists
Prof. Gerhard ECKER
(UNIVERSITY OF VIENNA, Vienna, Austria)
16:30European Lead Factory - Game Changing For Innovative Medicines
Dr Dimitrios TZALIS
(TAROS CHEMICALS, Dortmund, Germany)
17:00Funding Opportunities with the Innovative Medicines Initiative 2
Dr Colm CARROLL
(INNOVATIVE MEDICINES INITIATIVE, Brussels, Belgium)
17:30Poster Session I and Networking
19:30End of the day
20:30Concert (free of charge, but subject to registration)
Tuesday September 9, 2014
08:30Prize Ceremony
08:35EFMC Prize for a Young Medicinal Chemist in Industry
Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC
Dr Grazia PIIZZI
(NOVARTIS PHARMA, Basel, Switzerland)
08:55EFMC Prize for a Young Medicinal Chemist in Academia
Inhibitors and Substrates of the Human Lysine Deacylase Enzymes
Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)
09:15Plenary Lecture
Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)
10:00Exhibition & Coffee
4.8 Applications of Positron Emission Tomography in Drug Discovery
(ACS Session I)
4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers4.10 Organic Synthesis: New Developments
(EuCHemS Session)
10:30Session Chair
Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)
10:35PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery
Dr Peter J.H. SCOTT
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)
11:15A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development
Dr Chad ELMORE
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)
11:35Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging
Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)
11:55Quantitative Imaging of Mglu5 Allosteric Binding Site and its Occupancy by Positron Emission Tomography with The Novel Fluorine-18 Labelled Probe [18f]Pss232
Dr Stefanie KRAMER
(ETH ZÜRICH, Zürich, Switzerland)
10:30Session Chair
Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
10:35BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction
Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
11:15A First In Class Chemical Probe For Family VIII Bromodomains
Dr Dafydd OWEN
(PFIZER, Cambridge, United States)
11:35Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins
Prof. Paul FISH
(UCL SCHOOL OF PHARMACY, London, United Kingdom)
11:55Interrogation the Bromodomain Family through Chemical Biology
Dr Steve BELLON
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)
10:30Session Chair
Prof. Péter MÁTYUS (SEMMELWEIS UNIVERSITY, Budapest, Hungary)
 (THERMO FISHER SCIENTIFIC)
10:35Experiences with Natural Product Total Synthesis
Prof. Alois FÜRSTNER
(MAX PLANCK INSTITUT FUR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)
11:15New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds
Prof. Artur M.S. SILVA
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)
11:35Fast and Safe Synthesis of Pharmaceutically Relevant Molecules
Prof. Thomas WIRTH
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)
11:55Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases
Prof. Marko D. MIHOVILOVIC
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)
12:15Exhibition & Lunch
5.11 Oncology: Kinases and Beyond5.12 Recent Advances in Anti-infective Agents
(AFMC Session)
5.13 New Strategies for Lead Generation
13:15Session Chair
Dr Mario VARASI
(EUROPEAN INSTITUTE OF ONCOLOGY, Milano, Italy)
13:20Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer
Prof. Filippo MINUTOLO
(UNIVERSITY OF PISA, Pisa, Italy)
14:00Novel Anti-Cancer Treatment Targeting Vps34
Dr Jessica MARTINSSON
(SPRINT BIOSCIENCE, Stockholm, Sweden)
14:20Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors
Dr Maria Emilia DI FRANCESCO
(UTMD ANDERSON CANCER CENTER, Houston, United States)
14:40Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a
Dr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)
13:15Session Chair
Dr Ming-Hua HSU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)
13:20Development of New Anti-Infective Agents and a Novel Delivery Strategy
Prof. Reuben JIH-RU HWU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)
14:00Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds
Prof. Han-Young KANG
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)
14:20Novel Boron-containing Anti-infective Agents
Dr Jacob PLATTNER
(ANACOR PHARMACEUTICALS, Palo Alto, United States)
14:40Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists
Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
13:15Session Chair
Dr Maria BLANCO-PILLADO
(ELI LILLY AND COMPANY, Indianapolis, United States)
13:20Integration of New Chemical Diversity and Design Approaches in Lead Generation
Dr Timothy GRESE
(ELI LILLY AND COMPANY, Indianapolis, United States)
14:00The Impact of Polypharmacology on Lead Generation
Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)
14:20Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation
Dr Steve WOODHEAD
(TAKEDA CALIFORNIA, San Diego, United States)
14:40Discovery of the First and Only Small Molecule Il-17 Blockers
Dr Nils HANSEN
(VIPERGEN, Copenhagen, Denmark)
15:00Exhibition & Coffee
15:30Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery
Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
16:30Poster Session II and Networking
18:30End of the day
Wednesday September 10, 2014
08:30IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D
Dr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)
09:15Innovation Through Chemistry at the Interfaces of the Scientific Disciplines
Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)
10:00Exhibition & Coffee
6.14 New Chemical Entities: Beyond Small Molecules6.15 Novel Agents for the Treatment of C. Difficile
(ACS Session II)
6.16 Kinetic and Thermodynamic Aspects of Ligand Binding
10:30Session Chair
Prof. Stan VAN BOECKEL
(LEIDEN INSTITUTE OF CHEMISTRY, Leiden, The Netherlands)
10:35Cyclic Peptides from the nature to the synthetic ones
Prof. Fernando ALBERICIO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)
11:15Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics
Dr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)
11:35Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells
Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)
11:55Novel Inhibitors of Alzheimer's Associated Beta-Secretase-Clusters of Heparan Sulfate
Dr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)
10:30Session Chair
Prof. Steven FIRESTINE
(WAYNE STATE UNIVERSITY, Detroit, United States)
10:35Discovery and Development of Surotomycin for the Treatment of C. difficile
Dr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)
11:15Invited Lecture
Dr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)
11:35Targeting Spore Germination to Prevent Clostridium Difficile Infections
Dr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)
11:55Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Dr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)
10:30Session Chair
Prof. Gyorgy KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
10:35Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)
11:15Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.
Prof. Iwan DE ESCH
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
11:35Medicinal Chemistry Optimisation Of Binding Kinetics
Prof. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)
11:55CRTH2: Can Residence Time Help?
Dr Elena GOMEZ
(ALMIRALL, BARCELONA, Spain)
12:15Exhibition & Lunch
7.17 Recent Highlights in Medicinal Chemistry7.18 Hot Topics in Ion Channels7.19 Allosteric Modulators for CNS Diseases
13:15Session Chair
Prof. Carlos MONTANARI
(UNIVERSITY OF SAO PAULO, Sao Paulo, Brazil)
13:20Cebranopadol, a Novel, Potent Analgesic
Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)
13:40Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies
Dr Wolfgang SCHWEDE
(BAYER, Berlin, Germany)
14:00Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease
Dr Christopher LUCKHURST
(BIOFOCUS, Saffron Walden, United Kingdom)
14:20Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors
Dr Erin DIMAURO
(AMGEN, Cambridge, United States)
14:40Novel Potent Inhibitors of the Histone Demethylase KDM1A
Dr Paola VIANELLO
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)
13:15Session Chair
Prof. Brian COX
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Brighton, United Kingdom)
13:20An Introduction To Ion Channels As Drug Targets
Prof. Morten GRUNNET
(LUNDBECK, Valby, Denmark)
14:00CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study
Dr Gerard GIBLIN
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)
14:20Pain-relieving Peptides Targeting Acid-Sensing Ion Channels
Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)
14:40Discovery of Ivacaftor (Vx-770), a Cftr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients
Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)
13:15Session Chair
Dr Wolfgang FROESTL
(AC IMMUNE, Lausanne, Switzerland)
13:20Functional and Structural Insights into GPCR Allostery
Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Parkville, Australia)
14:00Discovery of the mGlu5 Negative Allosteric Modulator RO4917523
Dr Georg JAESCHKE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
14:20Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies
Prof. Ana MARTINEZ
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)
14:40Antibodies as Tools to Enable Small Molecule Drug Discovery
Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)
15:00Excursions
20:00Banquet
Thursday September 11, 2014
8.20 GPCR Structural Biology: New Therapeutic Opportunities?8.21 Neglected Tropical Diseases: Shaping Future Trends8.22 New Therapies for Metabolic Disorders
08:30Session Chair
Prof. Jan STEYAERT
(VUB, Brussels, Belgium)
08:35High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies
Dr. Jonathan MASON
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)
09:15Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs
Prof. Jan STEYAERT
(VUB, Brussels, Belgium)
09:35Covalent Agonists Facilitating Crystallisation of GPCRs
Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)
09:55Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening
Dr David RODRIGUEZ DIAZ
(STOCKHOLM UNIVERSITY, Solna, Sweden)
08:30Session Chair
Prof. Kelly CHIBALE
(UNIVERSITY OF CAPE TOWN, Cape Town, South Africa)
08:35Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites
Prof. Reto BRUN
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)
09:15Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery
Dr Adam RENSLO
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)
09:35Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box
Dr Francisco-Javier GAMO
(GLAXOSMITHKLINE, Madrid, Spain)
09:55Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei
Prof. Jennifer WOODRING
(NORTHEASTERN UNIVERSITY, Boston, United States)
08:30Session Chair
Dr Jürgen MACK
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)
08:35Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
09:151,1’-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Dr Thomas TRIESELMANN
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)
09:35Omarigliptin: A Once-weekly Oral Antidiabetic Agent
Dr Tesfaye BIFTU
(MERCK, Rahway, United States)
09:55Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism
Dr Anneli NORDQVIST
(ASTRAZENECA, Mölndal, Sweden)
10:15Exhibition & Coffee & Snacks
9.23 Late Breaking News9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling
10:45Session Chair
Dr Laurence LAFANECHERE
(CNRS, Grenoble, France)
10:50CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization
Dr Maurizio DELCANALE
(CHIESI, Parma, Italy)
11:10The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma
Dr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)
11:30Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases
Dr Franz VON NUSSBAUM
(BAYER PHARMA, Monheim, Germany)
11:50Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD
Dr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)
12:10Identifying Selective Inhibitors of FGFR4 Kinase
Dr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)
10:45Session Chair
Dr Andrew THOMAS
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
10:50CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson’s Disease
Prof. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)
11:30Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect
Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
11:50Fragment-Based Discovery of BACE Inhibitors for Alzheimer’s Disease
Dr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)
12:10The Evolution of an in vivo Efficacious Bace1 Inhibitor
Dr Daniel OEHLRICH
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)
10:45Session Chair
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
10:50Translational Modeling in Support to Discovery and Early Development
Dr Thierry LAVE
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
11:30Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721
Dr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)
11:50A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement
Mr Alban BUJARD
(UNIVERSITY OF GENEVA, Geneva, Switzerland)
12:10Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer
Dr Martyna KRZYKAWSKA-SERDA
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)
12:30Closing Lecture
Personalised Medicinal Systems Chemistry
Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
13:15Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2016

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys